Zantrene Highly Effective in a Mouse Model of Extramedullary AML

New Independent Study Identifies Activity of Zantrene in Type 2 Diabetes
25 January 2022 – Race Oncology Limited (“Race”) is pleased is pleased to share details…
Zantrene Improves Cancer Immunotherapy in a Mouse Model of Treatment Resistant Melanoma
22 June 2022 – Race Oncology Limited (“Race”) is pleased to share further interim results…
Zantrene shows impressive synergy with BRAF & MEK inhibitors in treating melanoma
28 June 2022 – Race Oncology Limited (“Race”) is pleased to share the final results…